key: cord-1005659-04arblh3
authors: Popert, Rick; Kum, Francesca; MacAskill, Findlay; Stroman, Luke; Zisengwe, Grace; Rusere, Jonah; Haire, Kate; Challacombe, Ben; Cathcart, Paul
title: Our First Month of Delivering the Prostate Cancer Diagnostic Pathway within the Limitations of COVID‐19 Using Local Anaesthetic Transperineal Biopsy
date: 2020-05-26
journal: BJU Int
DOI: 10.1111/bju.15120
sha: 017fa72e2ab985213af241fd27da200b57a2ff95
doc_id: 1005659
cord_uid: 04arblh3

The COVID‐19 pandemic is impacting all urological cancer services. On March 19(th) the British Association of Urological Surgeons (BAUS) provided pragmatic guidance for prostate cancer diagnostic services (Table 1).(1)

The COVID-19 pandemic is impacting all urological cancer services. On March 19 th the British Association of Urological Surgeons (BAUS) provided pragmatic guidance for prostate cancer diagnostic services ( Table 1) . (1) advance of the BAUS Guidance we suspended our transperineal (TP) biopsy service; however, a backlog of referrals remained. In February 2020, 101 MRIs were reviewed: 31 patients discharged for PSA observation; 61 listed for primary TP biopsy and 9 for AS TP biopsy. Patients with evidence of metastatic bone disease were started on hormonal therapy immediately, without biopsy. By 30 th March, 49 patients remained on the TP biopsy waiting list, so were stratified by priority with 15 Red, 15 Amber, 10 Green and 9 on AS ( Table 2) . We decided to re-start our prostate biopsy programme, but what are the logistics and how safe was it to proceed?

This article is protected by copyright. All rights reserved Aerosol generating procedures such as general anaesthetic (GA) are a significant risk for COVID-19 transmission to healthcare professionals.(2) COVID reverse-transcriptase-polymerase chain reaction (RT-PCR) has a sensitivity of only 83%, making a negative test unreliable, the safest approach is to assume all patients are positive and full Personal Protective Equipment (PPE) should be worn for intubation. GA TP Biopsy lists were cancelled, anaesthetists were redeployed to support Intensive Care. It was unlikely that GA TP biopsy lists will restart soon.

With limited access to GA, LA transrectal (LA TRUS) biopsy is an alternative but carries a high risk of post-biopsy related sepsis. At a time when intensive care beds are scarce, a 1.3% or greater risk of severe sepsis as reported by the National Prostate Cancer Audit is unjustifiable. (3, 4) There are further concerns that COVID-19 can be identified in faeces, but yet to be fully quantified.

COVID-19 appears to exploit angiotensin-converting-enzyme-2 (ACE2) for entry into target cells. 

Due to the safety concerns discussed above, a feasible solution is LA TP biopsy in the outpatient setting. 70% of TP prostate biopsies in our hospital are done under LA with only 20% requiring

This article is protected by copyright. All rights reserved intravenous sedation and 10% a GA. Around half are delivered in the Outpatients, the operator wearing simple gloves and an apron for what was considered a clean rather than a sterile procedure.

We were aware that other Urology Centres across the UK were continuing to offer LA TP biopsies much as before but to us, within London, in the midst of the COVID-19 pandemic, it seemed that simple gloves and an apron might not be sufficient protection for both staff or patient alike. We had to assume that all patients might be COVID-19 positive or recovering, with potentially live virus in their faeces. A TRUS probe is required to visualise the prostate, the rectum is filled with ultrasound gel, so the risk of faecal spillage should be considered. The operator's head and shoulders would be less than 1 metre from the patients' mouth and nose and the assistant would be within 2 metres.

Staff and patient safety are paramount and for this reason, it was decided that initially the procedure should be done with full PPE precautions, until timely robust testing becomes widely available.

The theatre matron, outpatient sister, disinfection and infection control teams were consulted for advice. Within 24 hours a "secure area" was established in outpatients with 4 rooms designated: Donning Room; Cold Room for trolley preparation; Hot Procedure Room for the biopsy and Doffing Room (Figure 1 ). With more outpatient clinics transitioning to remote telephone clinics, there was capacity for this layout. More recently, the need for a separate Doffing Room may be not be required, as doffing can safely be done in the Hot Procedure Room. This is an evolving model in line with Public Health England and Trust guidelines. Initially, the operator and assistant used full PPE for each case but in the interests of conserving PPE this has been modified. The operator wears the same FFP3 mask and visor for the entire 4 hour session, along with a waterproof plastic apron over theatre scrubs with plastic shoes and double gloves, which are changed after each case. The assistant wears gloves, a plastic apron, surgical face mask and visor. The first list was on 1 st April, five patients, stratified as in the Red category based on their PSA density and MRI, with no evidence of metastatic disease, were scheduled at hourly intervals.

Patients were initially screened by telephone, which included asking if they were isolating for any reason, 7 of 49 were shielded due to co-morbidities, therefore are being delayed. Patients were advised to drive or travel by taxi if possible. On arrival, they were screened with temperature, routine observations and a COVID-19 health questionnaire. Men were considered low risk for

This article is protected by copyright. All rights reserved COVID-19 infection if they were apyrexial, had no symptoms or any history of household/occupational exposure. All patients wore a surgical mask. To facilitate flow and training, 2 tandem teams of Surgeon, Clinical Nurse Specialist and Healthcare Assistant alternated. Equipment and surfaces in the Hot Room were cleaned between cases, according to infection control guidance, and 'dirty' disposables bagged securely in this room. All biopsies were completed under LA with no immediate complications. All patients received telephone follow-up within a week of the procedure.

One patient attended the Emergency Department with a fever and cough 2 days post-biopsy, had a normal chest x-ray and was COVID test negative. Since these first patients, we have successfully carried out 16 biopsies over the following 4 weeks ( Table 3) . 14/16 (88%) biopsies were 2-week-wait (2WW) referrals with one on Active Surveillance and one post-brachytherapy PSA rise, both had lesions on MRI. (31%) 5/16 were Black/Afro-Caribbean. Most men had a Target + Systematic biopsy, 3/16 (19%) had a Target biopsy only. The cancer pickup rate was 11/16 (69%) and ISUP ≥2 63% (10/16). The median Maximum Cancer Core Length was 10mm (range: 2-17mm) ( Table 3) . Table 3 

Whilst the net number of patients needing biopsies at our hospital over the next 8-12 weeks remains relatively small, scaled up across the whole Cancer Network may represent a significant number. The South East London Cancer Alliance stopped all TRUS biopsies in March 2019 and all 5 centres offer LA TP biopsies. In the COVID-19 era, it seems illogical for all centres to deliver a few TP biopsies in a potentially unsafe environment, without access to a 3 or 4-room outpatient setup. We have identified 2 sites within our Cancer Alliance that can carry out LA TP biopsies in a COVID-Secure Environment supported by a Network Urology Nurse Specialist and Consultant to continue delivering a limited, but carefully triaged, closely audited and safe prostate diagnostic capability for the entire Cancer Network.

This article is protected by copyright. All rights reserved As urologists, we need to plan how to deliver timely and safe prostate biopsies in the COVID-19 era, but with little indication of how long routine diagnostic services will be suspended. Across the UK there are more than 27 centres who already have extensive experience (>100 procedures) in delivering outpatient LA TP biopsies, cumulating to >7500 LA TP biopsies. The 18 Cancer Alliances have an opportunity to harness this experience and should be encouraged to support high quality prostate diagnostics under LA in outpatients, despite the challenges imposed by the pandemic.

There are opportunities to establish longitudinal studies on these patients, of whom up to half, by definition, would either be asymptomatic or have recovered from COVID-19. We could nationally determine whether faecal transmission is a true or hypothetical risk, but until we are certain, we strongly advocate that all TP biopsies should be offered under LA with appropriate PPE, to minimise the risk of COVID-19 transmission. 

This article is protected by copyright. All rights reserved 

This article is protected by copyright. All rights reserved Accepted Article

British Association of Urological Surgeons, Section of Oncology. COVID-19 strategy for the Interim management of Prostate Cancer

Association of Anaesthetists. COVID-19 Guidance

A Population-Based Cohort Study of the Impact of Infectious Complications Requiring Hospitalization after

The Royal College of Surgeons. National Prostate Cancer Audit

Prolonged presence of SARS-CoV-2 viral RNA in faecal samples

Accepted Article

Detection of SARS-CoV-2 in Different Types of Clinical Specimens